

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the bivalent COVID-19 mRNA vaccine (XBB.1.5/BQ.1 variants) (SYS6006.32) (the “**Product**”) developed by the Group has obtained clinical trial approval granted by the National Medical Products Administration of the People’s Republic of China.

SYS6006.32 is a bivalent COVID-19 mRNA vaccine containing XBB.1.5 and BQ.1 variants developed by the Group on the basis of the first generation COVID-19 mRNA vaccine (brand name: Duentai (度恩泰)), which has been included for emergency use in China. It is the first mRNA vaccine which targets dominant variants represented by XBB.1.5 in China. Non-clinical study data demonstrated that the Product not only induced very high immunogenicity against the dominant variants EG.5 and XBB.1.5, with the levels of live virus neutralizing antibody 108 and 88 times of those induced by Duentai respectively, but also induced broad-spectrum cross-variant immunity against mutant strains including XBB.1.16, XBB.1.9, BA.5, BQ.1 and BA.2.86. The Product had a good safety profile, with no additional risks as compared to Duentai.

With the advantages of the Group’s first generation COVID-19 vaccine in terms of safety, efficacy and industrialization, the Product was granted quick approval for clinical trials by the National Medical Products Administration under special approval procedures. The Group will expedite the promotion of emergency use of the Product.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 30 October 2023

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.